For the 3.8 million people in the United States with Alzheimer’s disease (AD) dementia, approved pharmacotherapy is limited to only modestly effective procognitive symptomatic agents (e.g., donepezil, memantine). Understanding today’s treatment landscape is important for emerging players as the heavily generic AD therapy market prepares for the potential entry of new, high-cost brands—namely, landmark disease-modifying therapies and new behavioral adjuncts. Our Treatment Algorithms: Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Eisai, Novartis, AbbVie, AstraZeneca, Eli Lilly, Johnson & Johnson, Lundbeck / Otsuka, Acadia Pharmaceuticals.
Key drugs: Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine IR, Namenda XR, Namzaric, antipsychotics, antidepressants.